Skip to main content
Equibles
REGN logo

REGN · Regeneron Pharmaceuticals, Inc.

Track REGN — free

Use REGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about REGN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$803.48 -2.49 (-0.31%) At close · Aug 14
Market Cap
$82.16B
Shares
102.95M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$803.48 Open$802.35 Day$792.57–806.54 52W close$555.51–812.27 Avg vol 30d780K Short int3.4M · 3.3% float · 3.9d Short vol61% Last earningsJul 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 3, 2026 Est · unconfirmed · in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +12%
      above
      Price vs 50-day avg +19%
      above
      RSI (14) 77
      overbought
      MACD trend Positive
      52-week position 97%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +19%
      trailing
      6-month return +2%
      trailing
      YTD return +4%
      this year
      Relative strength −12%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $676 › 200d $720 — 200d above 50d
      Institutional flow Distributing
      -7% holders QoQ · +121 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.29% of float · ▼ -3.3% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,304 holders — mid 3-yr range
      Squeeze score 54
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +21%
      Y/Y
      EPS growth +8%
      Y/Y
      Valuation P/E 19.8
      below peers
      Buyback $2.5B
      remaining
      Balance sheet $1.1B
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 34%
      annualized · 1-yr
      Max drawdown −26%
      past year
      ATR 2.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 30, 2026
      GAAP R&D · full year 2026 $6.5B – $6.64B
      Non-GAAP R&D · full year 2026 $5.95B – $6.05B
      Non-GAAP SG&A · full year 2026 $2.5B – $2.6B
      GAAP SG&A · full year 2026 $2.83B – $2.96B
      GAAP gross margin on net product sales · full year 2026 78% – 79%
      Non-GAAP gross margin on net product sales · full year 2026 84% – 85%
      GAAP COCM · full year 2026 $985M – $1.04B
      Non-GAAP COCM · full year 2026 $970M – $1.02B
      Capital expenditures · full year 2026 $1.03B – $1.1B
      GAAP effective tax rate · full year 2026 13% – 14%
      Non-GAAP effective tax rate · full year 2026 14% – 15%
      Prior guidance period ended · from the 8-K filed Jul 6, 2026
      GAAP and non-GAAP net income per diluted share · second quarter 2026 $-1.00

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +12% Bullish
      Price vs 50-day avg
      +19% Bullish
      RSI (14)
      77 Bearish
      MACD trend
      Positive Bullish
      52-week position
      97% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $676 › 200d $720 — 200d above 50d
      Institutional flow Distributing
      -7% holders QoQ · +121 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.29% of float · ▼ -3.3% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,304 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $556 Now $803 · 97% Range high $812
      vs 200-day avg +12% vs 50-day avg +19%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      EYLEA HD - U.S. $596M Q2 2026 —
      EYLEA HD® U.S. net sales $468M Q1 2026 —
      total EYLEA HD and EYLEA® U.S. net sales $941M Q1 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      REGN
      Regeneron Pharmaceuticals, Inc.
      this stock
      		$82.16B +4.1% +20.8% 19.8 3.3%
      ONC
      BeOne Medicines Ltd.
      		 $530.72B +14.4% +22179.2% 816.0 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $133.25B +11.6% +46.2% 30.6 1.6%
      ARGX
      Argenx SE
      		 $52.69B +1.2% — — 2.1%
      CSLLY
      Csl Ltd
      		 $46.19B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,304
      % held
      91.1%
      Net QoQ
      +3.1M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,510
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.4M
      Days to cover
      3.9d
      Change
      -115.4K sh
      View
      Short Volume
      Short vol %
      61%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      9
      Value
      $5.7K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      39.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      May 15, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $14.3B
      Net income (FY)
      $4.5B
      EPS diluted
      $41.48
      View
      Buybacks
      Authorized
      $3.0B
      Remaining
      $2.5B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $640.0K
      Shares
      800
      Filed
      Aug 10, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      REGN +2.4% +18.7% +2.1% +5.4% +4.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +2.0% +14.3% -11.7% +1.4% -9.8%

      Capital returns

      Latest dividend
      $0.94 / share · ex May 20, 2026
      Declared · upcoming
      $0.94 / share · ex Aug 18, 2026
      Raised 6.8%
      Paid (TTM)
      $3.64 / share · 4 payouts
      Dividend yield (TTM, derived)
      0.45%
      Buyback program · as of Jun 30, 2026
      Authorized
      $3.00B
      Spent (derived)
      $466.00M
      Remaining
      $2.53B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 872589 CUSIP 75886F107 13F (30d) 1219 filings 1179 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)